

08/26/99
JESS4 U.S. PRO

Attorney Docket No.: 6004.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Express Mail Label No. EL293692942US
Date of Deposit August 26, 1999

JC879 U.S. PRO
08/26/99

Sir:

This is a request for filing a patent application under 37 C.F.R. 1.53(b) of
Applicant(s): Belghith et al.

Title: Polypeptides Having Glucose Isomerase Activity And Nucleic Acids
Encoding Same

42 pages of specification 5 sheets of formal drawings

3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee: \$760.00

Total Claims: $22 - 20 = 2 \times 18 =$ \$ 36.00

Independent Claims: $4 - 3 = 1 \times 78 =$ \$ 78.00

Total Fee: \$874.00

Priority of Tunisian application no. SN 99.100 filed on May 26, 1999 is claimed
under 35 U.S.C. 119.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of
North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$874, to Novo Nordisk of North
America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: August 26, 1999

Carol E. Rozek
Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

Attorney Docket No.: 6004.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Belghuith et al.

Serial No.: TBA

Group Art Unit: TBA

Filed: August 26, 1999

Examiner: TBA

For: "Polypeptides Having Glucose Isomerase Activity And Nucleic Acids Encoding Same"

EXPRESS MAIL CERTIFICATE

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Express Mail Label No. EL293692942US

Date of Deposit August 26, 1999


I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Unexecuted Combined Declaration and Power of Attorney

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Miriam Kelly

(Name of person mailing paper(s) or fee)



(Signature of person mailing paper(s) or fee)

Mailing Address:

Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123